President Donald Trump announced Friday that all 50 states have agreed to participate in the Medicaid GENEROUS
drug-pricing model. The program utilizes international reference pricing to lower prescription costs, giving the administration a major health policy achievement ahead of November’s midterm elections.
President Donald Trump announced in the Oval Office that every state Medicaid program has signed on to the administration’s international drug-pricing model, known as GENEROUS. Flanked by health officials and Republican governors, Trump framed the nationwide rollout as a decisive victory for affordability as voters prepare for the midterm elections.
“This one thing alone should win us the midterms. It won’t, because the press doesn’t report it.”
President Donald Trump, via Yahoo News
The announcement expands the administration’s Most Favored Nation drug-pricing agenda, which aims to align U.S. prescription drug expenses with the costs paid in other developed countries. While the White House projects massive long-term savings, health policy researchers point to significant uncertainty regarding how much the initiative will actually reduce spending.
How the GENEROUS Medicaid Model Operates
The GENEROUS model, an acronym for GENErating cost Reductions fOr U.S. Medicaid,
functions through the existing Medicaid Drug Rebate Program. Administered by the Centers for Medicare & Medicaid Services, the five-year program permits federal officials to negotiate supplemental manufacturer rebates tied to foreign price benchmarks.
Under the framework, CMS calculates a target net price using pricing data from eight nations: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland. The benchmark relies on the second-lowest net international price after adjusting for purchasing power parity.
In exchange for voluntary participation, drug manufacturers receive a three-year reprieve from tariffs. More than two dozen major pharmaceutical firms, including Pfizer, Eli Lilly, and Novo Nordisk, have engaged with the pricing agreements. The initiative covers a broad spectrum of therapies, ranging from generic medicines and insulin to cancer treatments, cholesterol drugs, and specialized categories.
Projected Savings Versus Expert Skepticism
The White House maintains that broad international reference pricing will yield substantial relief for taxpayers. At Friday’s announcement, Trump emphasized that state governments would retain complete flexibility over those funds.
“Every state will have the ability to use those extra billions of dollars to invest in other healthcare improvements or something else.”
President Donald Trump, via The Associated Press
Independent health policy experts remain cautious about those projections.
Furthermore, transparency issues complicate independent verification. Because the administration has not publicly released the complete pharmaceutical agreements, researchers cannot fully determine which specific drugs will receive discounts or how participating manufacturers will select eligible products.
Transparency Concerns and the Risk of Cherry-Picking
The lack of public disclosure regarding the exact terms has drawn scrutiny from policy analysts.
“He is saying Congress should codify all of his MFN arrangements. But it’s kind of unreasonable because it’s not clear what Congress would actually do. No one knows what is in these deals.”
Kathy Hempstead, senior policy adviser at the Robert Wood Johnson Foundation, via The Associated Press
Similar warnings have been raised regarding the voluntary nature of the pilot program.
Public advocacy groups also argue that the program’s immediate footprint for everyday consumers may prove limited.
По теме
